|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
46,110,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile BioAtla is a biopharmaceutical company engaged in developing specific and selective antibody-based therapeutics for the treatment of various cancers. Co.'s lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and other tumor types. Co. also develops BA3021, a CAB ADC for NSCLC and Melanoma; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
81,495 |
83,495 |
252,735 |
Total Buy Value |
$0 |
$172,540 |
$177,620 |
$814,041 |
Total People Bought |
0 |
4 |
4 |
4 |
Total Buy Transactions |
0 |
4 |
5 |
15 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Waldron Richard A |
Chief Financial Officer |
|
2021-11-22 |
4 |
S |
$26.24 |
$95,128 |
D/D |
(3,626) |
162,965 |
|
- |
|
Steinman Lawrence |
Director |
|
2021-11-02 |
4 |
AS |
$30.00 |
$13,500 |
D/D |
(450) |
18,459 |
|
- |
|
Smith Scott Andrew |
President |
|
2021-10-01 |
4 |
S |
$30.18 |
$90,351 |
D/D |
(2,994) |
351,725 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2021-10-01 |
4 |
S |
$30.39 |
$17,993 |
D/D |
(592) |
93,174 |
|
- |
|
Levy Guy |
Director |
|
2021-09-30 |
4 |
A |
$28.00 |
$7,501,200 |
I/I |
267,900 |
1,115,817 |
|
- |
|
Steinman Lawrence |
Director |
|
2021-09-15 |
4 |
AS |
$36.82 |
$16,569 |
D/D |
(450) |
18,909 |
|
- |
|
Sievers Eric |
Chief Medical Officer |
|
2021-08-26 |
4 |
S |
$39.59 |
$272,496 |
D/D |
(6,883) |
93,766 |
|
- |
|
Smith Scott Andrew |
President |
|
2021-08-26 |
4 |
S |
$39.63 |
$1,334,927 |
D/D |
(33,244) |
354,719 |
|
- |
|
Levy Guy |
Director |
|
2021-08-24 |
4 |
S |
$39.65 |
$21,677,012 |
I/I |
(546,709) |
847,917 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2021-08-24 |
4 |
S |
$41.60 |
$188,573 |
I/I |
(4,533) |
793,547 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2021-08-24 |
4 |
OE |
$18.00 |
$139,446 |
I/I |
7,747 |
798,080 |
|
- |
|
Steinman Lawrence |
Director |
|
2021-08-16 |
4 |
AS |
$40.60 |
$18,270 |
D/D |
(450) |
19,359 |
|
- |
|
Steinman Lawrence |
Director |
|
2021-07-15 |
4 |
AS |
$38.29 |
$17,231 |
D/D |
(450) |
19,809 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2021-07-07 |
4 |
A |
$0.00 |
$0 |
D/D |
5,378 |
1,309,480 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2021-06-21 |
4 |
S |
$38.24 |
$2,152,373 |
I/I |
(55,000) |
790,333 |
|
- |
|
Short Jay M Phd |
Chief Executive Officer |
|
2021-06-17 |
4 |
S |
$39.22 |
$755,753 |
I/I |
(19,269) |
845,333 |
|
- |
|
Levy Guy |
Director |
|
2021-06-17 |
4 |
S |
$39.16 |
$15,664,000 |
I/I |
(400,000) |
270,553 |
|
- |
|
Mcbrinn Sylvia |
Director |
|
2021-06-15 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
425 |
|
- |
|
Himalaya Parent Llc |
10% Owner |
|
2021-06-14 |
4/A |
D |
$0.00 |
$0 |
D/D |
(8,682,254) |
50 |
|
- |
|
Pfizer Ventures (us) Llc |
10% Owner |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
I/I |
2,238,090 |
2,238,090 |
|
- |
|
Levy Guy |
Director |
|
2020-12-18 |
4 |
B |
$18.00 |
$25,000,020 |
I/I |
1,388,890 |
333,333 |
2.1 |
- |
|
Levy Guy |
Director |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,790,472 |
1,790,472 |
|
- |
|
Cormorant Private Healthcare Fund Ii, Lp |
10% Owner |
|
2020-12-18 |
4 |
B |
$18.00 |
$14,400,000 |
I/I |
800,000 |
2,292,060 |
1.5 |
- |
|
Cormorant Private Healthcare Fund Ii, Lp |
10% Owner |
|
2020-12-18 |
4 |
A |
$0.00 |
$0 |
I/I |
1,492,060 |
1,492,060 |
|
- |
|
Soleus Pe Gp I, Llc |
10% Owner |
|
2020-12-15 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
14,871 |
|
- |
|
211 Records found
|
|
Page 8 of 9 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|